

**PATENT COOPERATION TREATY**

**PCT**

**INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY**

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference P17023-DHWA	<b>FOR FURTHER ACTION</b>		See item 4 below
International application No. PCT/KR2017/008576	International filing date ( <i>day/month/year</i> ) 08 August 2017 (08.08.2017)	Priority date ( <i>day/month/year</i> ) 23 August 2016 (23.08.2016)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant DONG WHA PHARM. CO., LTD.			

<p>1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p>In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.</p>																								
<p>3. This report contains indications relating to the following items:</p> <table> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. I</td> <td>Basis of the report</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. II</td> <td>Priority</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. III</td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. IV</td> <td>Lack of unity of invention</td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>Box No. V</td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. VI</td> <td>Certain documents cited</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. VII</td> <td>Certain defects in the international application</td> </tr> <tr> <td><input type="checkbox"/></td> <td>Box No. VIII</td> <td>Certain observations on the international application</td> </tr> </table> <p>4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).</p>	<input checked="" type="checkbox"/>	Box No. I	Basis of the report	<input type="checkbox"/>	Box No. II	Priority	<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	<input type="checkbox"/>	Box No. IV	Lack of unity of invention	<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	<input type="checkbox"/>	Box No. VI	Certain documents cited	<input type="checkbox"/>	Box No. VII	Certain defects in the international application	<input type="checkbox"/>	Box No. VIII	Certain observations on the international application
<input checked="" type="checkbox"/>	Box No. I	Basis of the report																						
<input type="checkbox"/>	Box No. II	Priority																						
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																						
<input type="checkbox"/>	Box No. IV	Lack of unity of invention																						
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																						
<input type="checkbox"/>	Box No. VI	Certain documents cited																						
<input type="checkbox"/>	Box No. VII	Certain defects in the international application																						
<input type="checkbox"/>	Box No. VIII	Certain observations on the international application																						

	Date of issuance of this report 26 February 2019 (26.02.2019)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Kihwan Moon
Facsimile No. +41 22 338 82 70	e-mail: pct.team1@wipo.int

**PATENT COOPERATION TREATY**

**TRANSLATION**

From the  
INTERNATIONAL SEARCHING AUTHORITY

**PCT**

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To:

Date of mailing (day/month/year)	<b>16.11.2017</b>
-------------------------------------	-------------------

Applicant's or agent's file reference <b>P17023-DHWA</b>
---

<b>FOR FURTHER ACTION</b> See paragraph 2 below
--

International application No. <b>PCT/KR2017/008576</b>	International filing date (day/month/year) <b>08.08.2017</b>	Priority date (day/month/year) <b>23.08.2016</b>
---	---	---

International Patent Classification (IPC) or both national classification and IPC <b>C07C271/24 (2006.01) i, C07C269/06 (2006.01) i, C07C269/08 (2006.01) i</b>
--

Applicant <b>DONG WHA PHARM. CO., LTD.</b>
---

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/KR	Date of completion of this opinion	Authorized officer
Facsimile No.		Telephone No.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/KR2017/008576



Box No. I Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of:
  - the international application in the language in which it was filed
  - a translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2.  This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3.  With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing:
  - a.  forming part of the international application as filed:
    - in the form of an Annex C/ST.25 text file.
    - on paper or in the form of an image file.
  - b.  furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
  - c.  furnished subsequent to the international filing date for the purposes of international search only:
    - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
    - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
4.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:


WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.


PCT/KR2017/008576

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
1. Statement			
Novelty (N)	Claims	1-9	YES
	Claims	None	NO
Inventive step (IS)	Claims	None	YES
	Claims	1-9	NO
Industrial applicability (IA)	Claims	1-9	YES
	Claims	None	NO
2. Citations and explanations:			
Reference is made to the following document:			
D1: KR 10-2005-0110612 A (DAIICHI PHARMACEUTICAL CO., LTD.) 23 November 2005			
<b>2.1. Novelty and Inventive Step</b>			
D1 discloses a compound (reference example 144,			
			
(see paragraphs [1184]-[1186]); a compound (reference example 434), prepared from the compound of			
			


Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement




reference example 144 ( ) and the compound of




reference example 433 ( ) (see paragraphs



[2363]–[2369]); a compound ( , reference example 435), prepared by separating a Boc group from the compound of reference example 434 (see paragraphs [2371]–



[2373]); and a compound ( ), prepared from the compound of reference example 435 and a compound of



reference example 10 ( ) in embodiment 310 (see paragraphs [0621]–[0623] and [4380]–[4382]).

### 2.1.1. Claim 1

The compound represented by chemical formula 2 in claim 1 is different from the compound of reference example 144 in D1 in that the former compound is a succinate salt (see paragraphs

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

[1184]-[1186]). However, D1 provides organic acid salts such as oxalate salts, succinate salts, glutarate salts, tartrate salts, malate salts, etc., as examples of salts of the compound represented by chemical formula 1 (see paragraph [0183]). Furthermore, the present invention and D1 both relate to a compound having the same effect of exhibiting anticoagulant effects by inhibiting an activated blood coagulation factor X (FXa) (see paragraph [0001]). Thus, a person skilled in the art could easily select succinic acid from the organic acids to prepare a succinate salt of the compound, without any technical difficulty; and the effect resulting therefrom could be sufficiently predicted.

Therefore, claim 1 is novel under PCT Article 33(2), but lacks an inventive step under PCT Article 33(3) in light of D1.

#### **2.1.2. Claims 2 and 3**

Claims 2 and 3 relate to a compound represented by chemical formula 3 or 4, respectively. Each of the compounds is different from the compound of reference example 144 in D1 in that the former compounds are a tartrate salt or a citrate salt, respectively (see paragraphs [1184]-[1186]). However, as stated in item 2.1.1. above, D1 provides organic acid salts such as oxalate salts, succinate salts, glutarate salts, tartrate salts, malate salts, etc., as examples of salts of the compound represented by chemical formula 1 (see paragraph [0183]). Furthermore, the present invention and D1 both relate to a compound having the same effect of exhibiting anticoagulant effects by inhibiting an activated blood coagulation factor X (FXa) (see paragraph [0001]). Thus, a person skilled in the art could easily select tartaric acid or

**Box No. V** Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

citric acid from the organic acids to prepare a tartrate salt or a citrate salt of the compound, without any technical difficulty; and the effect resulting therefrom could be sufficiently predicted.

Therefore, claims 2 and 3 are novel under PCT Article 33(2), but lack an inventive step under PCT Article 33(3) in light of D1.

#### **2.1.3. Claim 4**

Claim 4 is different from D1 in that the claim relates to a method for preparing an acid addition salt, comprising: adding succinic acid, tartaric acid or citric acid to a reaction solution in which a compound represented by chemical formula 1 is dissolved in an organic solvent to prepare a mixture or sludge; and then heating and stirring the mixture or sludge. However, as stated in items 2.1.1. and 2.1.2. above, D1 discloses the compound of reference example 144 corresponding to the compound represented by chemical formula 1 in claim 4 (see paragraphs [1184]-[1186]), and provides organic acid salts such as oxalate salts, succinate salts, glutarate salts, tartrate salts, malate salts, etc., as examples of salts of the compound (see paragraph [0183]). Furthermore, the present invention and D1 both relate to a compound having the same effect of exhibiting anticoagulant effects by inhibiting an activated blood coagulation factor X (FXa) (see paragraph [0001]). Thus, a person skilled in the art could easily select succinic acid, tartaric acid or citric acid from the organic acids to prepare a succinate salt, a tartrate salt, or a citrate salt of the compound, without any technical difficulty; and the effect resulting therefrom could be

**Box No. V** Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

sufficiently predicted. In addition, the first step, second step and third step in claim 4 correspond to typical preparation steps used for preparing a salt compound, and thus could be derived by a person skilled in the art without any technical difficulty.

Therefore, claim 4 is novel under PCT Article 33(2), but lacks an inventive step under PCT Article 33(3) in light of D1.

#### **2.1.4. Claims 5 to 8**

Claim 5 referring to claim 4 limits the type of organic solvent, and said limitation is not disclosed in D1. However, an organic solvent to be used for preparing a salt compound could be derived by a person skilled in the art without any technical difficulty. It is not deemed that a remarkable effect is predicted therefrom.

Claims 6 to 8 refer to claim 4. Claim 6 limits the concentration range of the compound of chemical formula 1. Claim 7 limits the content of succinic acid, tartaric acid or citric acid with respect to the compound of chemical formula 1. Claim 8 limits the heating temperature. Said claims are different from D1 in that said limitations are not disclosed in D1. However, said difference could be optimized by a person skilled in the art through repeated experiments, without any technical difficulty. It is not deemed that said numerical limitations pose any particular technical difficulty, and it is not deemed that said numericals limitations have any critical significance. Thus, said difference could be easily implemented from D1, without any technical difficulty.



**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Therefore, claims 5 to 8 are novel under PCT Article 33(2), but lack an inventive step under PCT Article 33(3) in light of D1.

**2.1.5. Claim 9**

Claim 9 is different from D1 in that the claim uses, in the first step, an acid addition salt represented by any one of chemical formulas 2 to 4. However, as stated in items 2.1.1. and 2.1.2. above, D1 discloses the compound of reference example 144 corresponding to the compound represented by chemical formula 1 in claim 4 (see paragraphs [1184]-[1186]), and provides organic acid salts such as oxalate salts, succinate salts, glutarate salts, tartrate salts, malate salts, etc., as examples of salts of the compound (see paragraph [0183]). Furthermore, the present invention and D1 both relate to a compound having the same effect of exhibiting anticoagulant effects by inhibiting an activated blood coagulation factor X (FXa) (see paragraph [0001]). Thus, a person skilled in the art could easily select succinic acid, tartaric acid or citric acid from organic acids to prepare a succinate salt, a tartrate salt, or a citrate salt of the compound, without any technical difficulty; and the effect resulting therefrom could be sufficiently predicted. In addition, D1 discloses, in example 310, a compound prepared from the compound of reference example 435 and the compound of reference example 10, which corresponds to edoxaban represented by chemical formula A in claim 9 (see paragraphs [0621]-[0623] and [4380]-[4382]).

Therefore, claim 9 is novel under PCT Article 33(2), but lacks an inventive step under PCT Article 33(3) in light of D1.

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## 2.2. Industrial Applicability

The invention as set forth in claims 1 to 9 is industrially applicable under PCT Article 33(4).

### [Note]

- Edoxaban represented by chemical formula A in claim 9 is a compound prepared from "the acid addition salt represented by any one of formulas 2 to 4 prepared according to claim 4." However, the substitution site of "N,N-dimethylcarbamoyl" in the acid addition salt of chemical formulas 2 to 4 and the substitution site of "N,N-dimethylcarbamoyl" in edoxaban of chemical formula A are inconsistent with each other. Thus, in order to make the subject matter clearer, it would be desirable to make the substitution sites of "N,N-dimethylcarbamoyl" of these chemical formulas consistent. (For reference, the present international search report and written opinion have been established under the assumption that the substitution site of "N,N-dimethylcarbamoyl" in edoxaban represented by chemical formula A in claim 9 is the substitution site of chemical formulas 2 to 4 in claim 4.)